Manufacturing: Biolexis to produce AmbiVax-CTM in India-130+ countries


Veeda Clinical Research managed Phase II/III trial Biolexis, the vaccine and biosimilar arm of the Strides Group, is to manufacture and commercialize AmbiVax-CTM in India and over 130 countries in Asia, Latin America, and Africa, mainly covering the low-and-middle-income countries (LMICs) where a significant population lacks dependable access to vaccines as a result of insufficient...

Please subscribe to read
Log In Join Now